Reclast

Primary Uses

Reclast is primarily prescribed to strengthen bones and reduce the risk of fractures in several specific conditions:

• Postmenopausal Osteoporosis: It is used to treat and prevent osteoporosis in women who have gone through menopause. It helps reduce the risk of hip and spinal fractures.
• Osteoporosis in Men: It is used to increase bone mass in men with osteoporosis.
• Steroid-Induced Osteoporosis: It is used to treat and prevent osteoporosis in men and women who are starting or taking glucocorticoid medicines (steroids) for a long period of time.
• Paget's Disease of Bone: It is used to treat Paget's disease, a condition where bones become enlarged, weak, and prone to deformity or fracture.

Clinical Applications

In patients with osteoporosis, Reclast works by slowing down the rate at which bone is broken down, which helps to increase bone density and lower the chance of breaking a bone. For Paget's disease, it helps return the bone remodeling process to a more normal state. It may also be used to reduce the risk of new clinical fractures in patients who have recently had a low-trauma hip fracture.

Bone Remodeling

Bone is a living tissue that is constantly changing. Throughout life, the body performs a process called remodeling, where old bone is broken down and replaced with new bone. In healthy adults, the rate of bone breakdown and bone formation is usually balanced.

Slowing Bone Loss

In conditions like osteoporosis or Paget's disease, the cells that break down bone, called osteoclasts, become more active than the cells that build it. This leads to a loss of bone density, making bones weaker and more likely to break. Reclast works by targeting this process in the following ways:

• Inhibiting osteoclasts: The medication binds to the mineral surface of the bone. When osteoclasts attempt to break down the bone tissue, they absorb the medication, which slows their activity and reduces bone resorption.
• Increasing bone mass: By reducing the rate at which bone is lost, the body is better able to maintain or increase bone mineral density over time.
• Reducing fracture risk: Strengthening the internal structure of the bone helps prevent fractures in the hip, spine, and other vulnerable areas.

Because the medication binds directly to the bone mineral, its effects can last for a long period. This long-lasting action is why the medication is typically administered as an intravenous infusion only once a year or once every two years, depending on the specific condition being treated.

Common Side Effects

Many people experience flu-like symptoms within the first three days after receiving a Reclast infusion. These symptoms usually go away within a few days and may include:

• Fever and chills
• Muscle, joint, or bone pain
• Headache
• Nausea, vomiting, or diarrhea
• Fatigue or weakness
• Dizziness
• Pain or swelling in the arms or legs

Serious Side Effects

While less common, some side effects require immediate medical attention. Contact a healthcare provider right away if you experience:

• Kidney problems: Signs include decreased urination, swelling in the feet or ankles, or unusual tiredness.
• Low blood calcium: Symptoms may include muscle spasms, twitches, cramps, or numbness and tingling in the fingers, toes, or around the mouth.
• Jaw problems: Severe pain, swelling, or sores in the mouth or jaw that do not heal, or loose teeth.
• Unusual fractures: New or unusual pain in the hip, groin, or thigh.
• Severe pain: Intense pain in the bones, joints, or muscles that makes movement difficult.
• Eye issues: Eye pain, redness, or changes in vision.
• Irregular heartbeat: A feeling of a racing or skipping heartbeat.

Kidney Health

Reclast is associated with a risk of sudden kidney failure. It is contraindicated for people with severe kidney impairment (creatinine clearance less than 35 mL/min) or those with acute kidney injury. Healthcare providers typically perform blood tests to check kidney function before each dose to ensure the medication can be administered safely.

Low Blood Calcium

Pre-existing low blood calcium (hypocalcemia) must be treated before receiving Reclast. This medication can further lower calcium levels, which may lead to muscle spasms, numbness, or seizures. Adequate intake of calcium and vitamin D is usually recommended during treatment to prevent this complication.

Bone and Jaw Concerns

• Osteonecrosis of the Jaw: This is a rare but serious condition where the jawbone is exposed and begins to die. Risk factors include poor oral hygiene, invasive dental procedures (such as tooth extractions), and certain health conditions like cancer or anemia.
• Atypical Femur Fractures: Some patients may experience unusual fractures in the thigh bone. New or unusual pain in the hip, groin, or thigh should be reported to a healthcare provider immediately.
• Severe Pain: Severe and occasionally incapacitating bone, joint, or muscle pain may occur at any time during treatment.

Post-Infusion Symptoms

Many people experience flu-like symptoms within three days of the infusion, such as fever, fatigue, chills, and muscle aches. These symptoms are generally mild to moderate and usually resolve within a few days.

Other Precautions

Reclast may cause inflammation in the eyes (uveitis or iritis). If redness, pain, or vision changes occur, medical attention is necessary. Additionally, this medication may cause harm to an unborn baby and is generally not recommended for use during pregnancy or while breastfeeding.

Pregnancy

Reclast may cause harm to an unborn baby and is generally not recommended for use during pregnancy. It is important to notify a healthcare provider if you are pregnant or planning to become pregnant before starting treatment.

Because Reclast stays in the bone matrix for a long period of time, there is a theoretical risk that the drug could affect a fetus even if pregnancy occurs years after the last dose. The impact of this long-term exposure on fetal development is not yet fully understood.

Breastfeeding

It is currently unknown if Reclast passes into human breast milk. Because of the potential for serious side effects in a nursing infant, healthcare providers usually recommend caution. Patients should consult with their doctor to weigh the risks and benefits of breastfeeding while using this medication.

Available Forms

Reclast is provided as a sterile solution for administration into a vein. It is available in the following form:

• Intravenous Infusion: A liquid solution supplied in a bottle for administration through a needle or catheter.

This medication is administered by a healthcare provider, typically in a doctor's office or infusion center. It is not available in oral forms such as tablets or capsules.

FDA Approval and Indications

Reclast is FDA-approved for the treatment and prevention of osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis. It is also indicated for the treatment and prevention of glucocorticoid-induced osteoporosis and for the treatment of Paget's disease of the bone.

Safety Communications

The FDA has issued safety communications regarding the risk of kidney failure associated with Reclast. In 2011, the drug label was updated to include a contraindication for patients with severe kidney impairment (creatinine clearance less than 35 mL/min) or acute kidney failure. Healthcare providers are required to screen patients' serum creatinine levels before each dose to monitor kidney function.

Regulatory Warnings

The FDA monitors several serious but rare risks associated with bisphosphonates like Reclast, including:

• Osteonecrosis of the jaw: This condition involves the death of jawbone tissue and is often linked to invasive dental work.
• Atypical femur fractures: These are unusual fractures of the thigh bone that can occur even with minimal trauma.
• Severe musculoskeletal pain: Some patients may experience debilitating bone, joint, or muscle pain after starting treatment.

Administration Process

Reclast is delivered directly into a vein through an intravenous (IV) line. The infusion process must last at least 15 minutes to ensure the medication is delivered safely. It is administered by a doctor or nurse in a clinical setting, such as a hospital or infusion center.

Preparation and Hydration

Proper hydration is essential before and after receiving the infusion. Patients are generally advised to:

• Drink at least two glasses of water (about 2 cups) shortly before the infusion.
• Continue drinking plenty of fluids for the remainder of the day after the procedure.

Infusion Schedule

The frequency of Reclast infusions depends on the medical reason for the treatment:

• Osteoporosis treatment: Usually given once every year.
• Osteoporosis prevention: Usually given once every two years.
• Paget's disease: Often administered as a single dose, though additional doses may be needed if the condition recurs.

Post-Infusion Reactions

It is common to experience flu-like symptoms after the first infusion, such as fever, chills, muscle aches, or joint pain. These symptoms typically begin within three days of the infusion and usually resolve within three days. Taking acetaminophen shortly after the infusion may help reduce these side effects.